ライフサイエンスコーパス: indocyanine green

1 ation of theranostic agents (doxorubicin and indocyanine green).

2 t encapsulate the near infrared chromophore, indocyanine green.

3 following intravenous injection of 10 mg/kg indocyanine green.

4 e hydrophilic analogs of clinically approved indocyanine green.

5 ved the poor performance of the FDA-approved indocyanine green.

6 ntroducing a near-infrared (NIR) dye such as indocyanine green.

7 stic signals compared with the commonly used indocyanine green.

8 All patients received intravenous indocyanine green (75 mg) between 16 and 24 hours before

9 The clinically applied hybrid tracer indocyanine green-(99m)Tc-nanocolloid enables combined r

10 ere considered candidates for SN biopsy with indocyanine green-(99m)Tc-nanocolloid or (99m)Tc-nanocol

11 e cancer during an SN biopsy procedure using indocyanine green-(99m)Tc-nanocolloid.

12 Indocyanine green, a near-infrared fluorescent dye that

13 Indocyanine green and BPD angiography were performed in

14 liposomes loaded with an optimized ratio of indocyanine green and doxorubicin, denoted as LID, effic

15 ting (electrophysiology, fundus photography, indocyanine green and fluorescein angiography, and magne

16 mography (OCT), fundus autofluorescence, and indocyanine green and fluorescein angiography, was avail

17 nusoidal endothelial cells were evaluated by indocyanine green and hyaluronic acid uptake.

18 Indocyanine green and OCT angiography revealed numerous

19 eceived a standardised cervical injection of indocyanine green and sentinel-lymph-node mapping follow

20 amine 800, Alexa Fluor 750, IRDye 800CW, and indocyanine green) and proteins (sfGFP, mCherry, mKate,

21 ction frequency via near-infrared imaging of indocyanine green, and ankle bone volumes via micro-comp

22 uated the in vivo uptake of hyaluronic acid, indocyanine green, and radio-labeled sulphur colloid to

23 milar heptamethine fluorophores ZW800-1A and indocyanine green, and show that ZW800-1C undergoes a lo

24 fundus photographs, fluorescein angiograms, indocyanine green angiograms, and optical coherence tomo

25 he success rate of laser treatment guided by indocyanine green angiographic findings can vary conside

26 in an area of hypofluorescence on late-phase indocyanine green angiographic images.

27 ng color fundus photography, fluorescein and indocyanine green angiographies, spectral-domain optical

28 luding retinography, SD-OCT, fluorescein and indocyanine green angiography (FA & ICGA) and adaptive o

29 tients underwent fluorescein angiography and indocyanine green angiography (FA/ICGA), swept-source or

30 T, fundus fluorescein angiography (FFA), and indocyanine green angiography (ICG) by 2 independent obs

31 Indocyanine green angiography (ICG) was used to identify

32 s photography, fluorescein angiography (FA), indocyanine green angiography (ICG), optical coherence t

33 ce (FAF), OCT, fluorescein angiography (FA), indocyanine green angiography (ICGA) and OCT angiography

34 atients diagnosed with CSC who underwent UWF indocyanine green angiography (ICGA) and widefield OCT i

35 To investigate indocyanine green angiography (ICGA) findings in patient

36 Concurrent fluorescein angiography (FA) and indocyanine green angiography (ICGA) images were used to

37 nce (FAF), fluorescein angiography (FA), and indocyanine green angiography (ICGA) imaging to evaluate

38 Indocyanine green angiography (ICGA) showed central hypo

39 escence in the topography of the lesion, and indocyanine green angiography (ICGA) showed hypofluoresc

40 l choroidal vasculopathy was diagnosed using indocyanine green angiography (ICGA) with the scanning l

41 (FAF), fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), and OCT angiograph

42 escence (FAF), fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical cohere

43 escence (FAF), fluorescein angiography (FA), indocyanine green angiography (ICGA), and SD-OCT were pe

44 hy (OCTA), fluorescein angiography (FA), and indocyanine green angiography (ICGA), and the images fro

45 imultaneous fluorescein angiography (FA) and indocyanine green angiography (ICGA), enhanced-depth ima

46 (OCT), fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), fundus autofluores

47 al vasculopathy (PCV) is best diagnosed with indocyanine green angiography (ICGA), ICGA is often unav

48 (CFP), fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), optical coherence

49 eflectance, fundus autofluorescence imaging, indocyanine green angiography (ICGA), preferential hyper

50 obtained using fluorescein angiography (FA), indocyanine green angiography (ICGA), structural optical

51 ts except for choroidal hyperpermeability on indocyanine green angiography (ICGA).

52 hypofluorescence of the plaque on late-phase indocyanine green angiography (ICGA).

53 he entire fundus using ultra-widefield (UWF) indocyanine green angiography (ICGA).

54 d imaging, fluorescein angiography (FA), and indocyanine green angiography (ICGA).

55 our department, 167 cases were confirmed by indocyanine green angiography (ICGA).

56 icolor imaging, fluorescein angiography, and indocyanine green angiography (ICGA).

57 CT, OCT-A, fluorescein angiography (FA), and indocyanine green angiography (ICGA).

58 data on demographics, clinical features, and indocyanine green angiography (ICGA).

59 rate vitritis, and hypocyanescent lesions on indocyanine green angiography (ICGA).

60 tations of venous overload on ultrawidefield indocyanine green angiography (UWF ICGA) include asymmet

61 olypoidal lesion (PL) closure at week 12 per indocyanine green angiography .

62 Baseline fluorescein angiography and indocyanine green angiography also were performed.

63 Advances in imaging, particularly in indocyanine green angiography and optical coherence tomo

64 nd fundus imaging, including fluorescein and indocyanine green angiography and optical coherence tomo

65 patients with extrafoveal PCV, confirmed on indocyanine green angiography and treated with argon las

66 In dry macular degeneration, indocyanine green angiography appears to add clinically

67 In certain circumstances, indocyanine green angiography can be valuable in detecti

68 Indocyanine green angiography confirmed choroidal inflam

69 Infrared thermography and indocyanine green angiography confirmed the presence of

70 vidence of retinal vasculitis or papillitis, indocyanine green angiography evidence of active choroid

71 Indocyanine green angiography excluded Vogt-Koyanagi-Har

72 Indocyanine green angiography findings, particularly at

73 refraction, colour imaging, fluorescein and indocyanine green angiography findings, together with B-

74 Indocyanine green angiography has allowed us to look at

75 For the past year, indocyanine green angiography has been applied to evalua

76 sarcoidosis in intraocular inflammation, and indocyanine green angiography has clarified choroidal in

77 The relative safety of indocyanine green angiography has contributed to its con

78 developments in the clinical application of indocyanine green angiography have mainly concerned refi

79 ted color fundus photographs fluorescein and indocyanine green angiography images to determine the su

80 coherence tomography [OCT], fluorescein and indocyanine green angiography images) were analyzed.

81 ptical coherence tomography, fluorescein and indocyanine green angiography in a 66 years old man suff

82 t-naive patients diagnosed with PCV based on indocyanine green angiography in accordance with publish

83 rrelated with the polypoidal lesions seen on indocyanine green angiography in all PCV eyes.

84 erns of abnormal hyperfluorescence seen with indocyanine green angiography in eyes with both wet and

85 al coherence tomography, and fluorescein and indocyanine green angiography in patients suspected of h

86 udies demonstrating choroidal involvement by indocyanine green angiography in patients with HTLV-1-as

87 Indocyanine green angiography is improving our understan

88 defield fluorescein angiography results, and indocyanine green angiography results were collected.

89 Indocyanine green angiography revealed chroidal vascular

90 Indocyanine green angiography revealed dilated hyperperm

91 Indocyanine green angiography revealed the presence of c

92 Indocyanine green angiography revealed tortuous choroida

93 d 1970s, the introduction of fluorescein and indocyanine green angiography revolutionized our ability

94 was confirmed by fluorescein angiography and indocyanine green angiography testing.

95 Upon comparison with indocyanine green angiography videoangiography (ICG-VA)

96 Indocyanine green angiography was performed at baseline

97 nding hypofluorescence in 100% of cases when indocyanine green angiography was performed.

98 ence tomography angiography, fluorescein and indocyanine green angiography was performed.

99 nce tomography, fluorescein angiography, and indocyanine green angiography were graded.

100 us examination, fluorescein angiography, and indocyanine green angiography were included.

101 olor images, and fluorescein angiography and indocyanine green angiography were measured before and a

102 l diameter and thickness and fluorescein and indocyanine green angiography were no different in the 2

103 Fluorescein and indocyanine green angiography were performed in patients

104 FA), optical coherence tomography (OCT), and indocyanine green angiography were performed.

105 dalities such as magnetic resonance imaging, indocyanine green angiography, and digital image analysi

106 th fundus photography, OCT, OCT angiography, indocyanine green angiography, and fluorescein angiograp

107 depth imaging-OCT, fluorescein angiography, indocyanine green angiography, and fundus autofluorescen

108 as ultrasonography, fluorescein angiography, indocyanine green angiography, and magnetic resonance im

109 rements, fundus photography, fluorescein and indocyanine green angiography, and microperimetry.

110 uorescence imaging, fluorescein angiography, indocyanine green angiography, and optical coherence tom

111 sion, quality of life (QoL), fluorescein and indocyanine green angiography, and optical coherence tom

112 Ophthalmic CT, fluorescein angiography, indocyanine green angiography, and others are demonstrat

113 ser ophthalmoscopy, fluorescein angiography, indocyanine green angiography, and spectral-domain optic

114 ncluding fundus photography, fluorescein and indocyanine green angiography, fundus autofluorescence i

115 ddition, a subset of patients also underwent indocyanine green angiography, fundus fluorescein angiog

116 color photography, fluorescein angiography, indocyanine green angiography, near-infrared reflectance

117 prised fundus photography, autofluorescence, indocyanine green angiography, OCT, and OCT angiography.

118 s autofluorescence, fluorescein angiography, indocyanine green angiography, optical coherence tomogra

119 uorescence imaging, fluorescein angiography, indocyanine green angiography, or a combination thereof.

120 reaks and reduced fluorescence on late-phase indocyanine green angiography, prompted genetic testing

121 amination including fluorescein angiography, indocyanine green angiography, spectral-domain optical c

122 onography, OCT, fluorescein angiography, and indocyanine green angiography, was performed throughout

123 l imaging, including OCT and fluorescein and indocyanine green angiography, was reviewed for the pres

124 randomized at a 1:1 ratio to receive either indocyanine green angiography-guided half-dose PDT or or

125 ated with either half-dose PDT or HSML (both indocyanine green angiography-guided) and categorized in

126 omography, fluorescein angiography (FA), and indocyanine green angiography.

127 erence tomography (OCT), and fluorescein and indocyanine green angiography.

128 for fluorescence, including fluorescein and indocyanine green angiography.

129 ography, fundus fluorescein angiography, and indocyanine green angiography.

130 er with symptomatic macular PCV confirmed on indocyanine green angiography.

131 hy, and lack of choroidal vascular lesion on indocyanine green angiography.

132 birdshot spots" or characteristic imaging on indocyanine green angiography.

133 that corresponded to hypocyanescent spots on indocyanine green angiography.

134 flow" and "low-flow" region eyes followed by indocyanine green angiography.

135 th autofluorescence, SD-OCT, fluorescein and indocyanine green angiography.

136 fundus autofluorescence, and fluorescein and indocyanine green angiography.

137 tofluorescence, fluorescein angiography, and indocyanine green angiography.

138 good correlation with lesions identified on indocyanine green angiography.

139 lar evaluation by a simultaneous fluorescein/indocyanine green angiography.

140 t, and regression of polypoidal complexes on indocyanine green angiography.

141 Indocyanine-green angiography (ICG-A) may be considered

142 tofluorescence, fluorescein angiography, and indocyanine-green angiography (ICGA).

143 intravenous fluorescein angiography (IVFA), indocyanine-green angiography, and ophthalmic ultrasound

144 Trypan Blue and Indocyanine Green appear to be most effective in stainin

145 ger-scale studies are essential to establish indocyanine green as a viable alternative rather than a

146 At the time of reperfusion, indocyanine green-based in vivo imaging showed that CD47

147 Administration-cleared devices designed for indocyanine green-based perfusion imaging to identify ca

148 Intraoperative visualization of the SLN by indocyanine green before skin incision was successful in

149 , microvascular quadriceps blood flow index (indocyanine green), cardiac output (inert gas breathing)

150 tly faster lymphatic drainage as measured by indocyanine green clearance and increased lymphatic vess

151 llular function was determined by an in vivo indocyanine green clearance technique.

152 Indocyanine green clearance was measured in two animals

153 lationship between the increments in VO2 and indocyanine green clearance was observed (r2 = .21; p =

154 e maximal velocity and efficiency of in vivo indocyanine green clearance) was determined and hepatocy

155 l velocity and overall efficiency of in vivo indocyanine green clearance) were assessed at 24 hours a

156 ximum velocity and the overall efficiency of indocyanine green clearance) were determined at 4 hrs af

157 ximum velocity and the overall efficiency of indocyanine green clearance) were determined.

158 Indocyanine green clearance, as determined by a fiberopt

159 A noninvasive measurement of indocyanine green clearance, the plasma disappearance ra

160 velocity and transport efficiency of in vivo indocyanine green clearance.

161 , N-acetylcysteine elicits an improvement in indocyanine green clearance.

162 ut not VO2) and a nonsignificant increase in indocyanine green clearance.

163 hanced the tumor targeting of GSH-responsive indocyanine green-conjugated Au(25) nanoclusters coated

164 The number of new indications for indocyanine green continues to increase, including innov

165 ulating blood volume were assessed using the indocyanine green dilution technique and a left ventricu

166 shifted julolidine flavylium heterocycle and indocyanine green, distinct channels with well-separated

167 When indocyanine green dosages were 10 microg or higher, lymp

168 ear-infrared (NIR) fluorescence imaging with indocyanine green during resection of bone and soft tiss

169 Indocyanine green dye (0.08 mg/ml in D5W) was injected s

170 EGF-Cy5.5, but not Cy5.5 or indocyanine green dye (ICG), bound to MDA-MB-468 cells.

171 The current mapping agent, indocyanine green dye cannot be externally imaged prior

172 ith 50- to 100-fold greater concentration of Indocyanine Green dye over background levels.

173 f the PKWS subject that transported injected indocyanine green dye to the inguinal lymph node and dra

174 Near-infrared reflectance measurements of indocyanine green dye uptake indicated that there were n

175 Indocyanine green dye was used as a nonspecific control

176 oxorubicin and photothermally active organic indocyanine green dye).

177 ining of the internal limiting membrane with indocyanine green dye, and variations in the length of p

178 nin and choroidal vessels using FDA-approved indocyanine green dye-enhanced PAM imaging.

179 Indocyanine green elimination constants (K(ICG)) were me

180 asers, combined with the clinically approved indocyanine green, enabled real-time, three-colour imagi

181 Based upon Indocyanine Green encapsulation within the nanoparticles

182 al nonimmobilized limb, confirmed by in vivo indocyanine green-enhanced NIR optical imaging (3.86-fol

183 of muscle damage was obtained using in vivo indocyanine green-enhanced NIR optical imaging, magnetic

184 Fusion of indocyanine green-enhanced optical imaging and radiograp

185 Indocyanine green-enhanced optical imaging is a clinical

186 Fusion of indocyanine green-enhanced optical imaging scans with ra

187 Mean rates of bile flow, biliary indocyanine green excretion, and bile acid flux were sig

188 Indocyanine green fluorescence imaging demonstrated comp

189 Indocyanine green fluorescence imaging is a surgical too

190 ependent or that refine the existing method: indocyanine green fluorescence, contrast-enhanced ultras

191 ls in the upper extremities, especially when indocyanine green fluorescent lymphography fails to depi

192 cutaneous melanoma on the trunk), the use of indocyanine green for SLN detection is severely limited

193 n wavelength) fluorescence (by using the dye indocyanine green) for aiding the fluorescence-guided su

194 TATION: Sentinel lymph nodes identified with indocyanine green have a high degree of diagnostic accur

195 Subjects received second window indocyanine green (ICG) (2.5-5 mg/kg) 24 hours prior to

196 frared (NIR) fluoresence dental imaging with indocyanine green (ICG) agent that has rarely been appli

197 ode tracer consisting of the fluorescent dye indocyanine green (ICG) and (99m)Tc-nanocolloid with the

198 Indocyanine green (ICG) and epirubicin (EPI) could co-se

199 n-based nano-formulations capable of loading indocyanine green (ICG) and therapeutic genes were prepa

200 in infrared reflectance (IR) photographs and indocyanine green (ICG) angiograms.

201 orescence (FAF), and fluorescein angiography/indocyanine green (ICG) angiography findings, of patient

202 Indocyanine green (ICG) angiography has been successfull

203 Indocyanine green (ICG) aqueous angiography established

204 glycated chitosan (GC) as immunoadjuvant and indocyanine green (ICG) as laser-absorbing dye have show

205 infrared (NIR) range, clinical potential of indocyanine green (ICG) as PT is limited by its short ha

206 Liver function was assessed by clearance of indocyanine green (ICG) at 4, 20 and 28 hours.

207 ood flow and function were determined by the indocyanine green (ICG) clearance test.

208 We report indocyanine green (ICG) conjugated with a 2100 Da PEG mo

209 The near-infrared dye indocyanine green (ICG) could serve as a basis for such

210 noJagg probe is obtained by self-assembly of indocyanine green (ICG) dimers using a scalable manufact

211 targeted liposomes loaded with J-aggregated indocyanine green (ICG) dye (i.e., PAtrace) that we synt

212 otic shock technique was used to encapsulate indocyanine green (ICG) dye in erythrocyte ghost cells a

213 /J mice was induced by combined injection of indocyanine green (ICG) dye into the anterior chamber an

214 velocimetry (EMV) is a novel technique where indocyanine green (ICG) dye is sequestered in erythrocyt

215 and tissues in vivo, which differs from the indocyanine green (ICG) dye.

216 espectively tracked iron oxide particles and indocyanine green (ICG) encapsulated in the NPs as trace

217 ogenase (LDH) activity, bile production, and indocyanine green (ICG) extraction.

218 trate the predictive ability of quantitative indocyanine green (ICG) fluorescence angiography for the

219 Indocyanine green (ICG) fluorescence imaging could be us

220 OCT and indocyanine green (ICG) fluorescence were used to evalua

221 secondary lymphedema in the extremities, but indocyanine green (ICG) fluorescent lymphography, the re

222 tomography (DOT) after the administration of indocyanine green (ICG) for contrast enhancement.

223 Hyperfluorescent cells labeled with indocyanine green (ICG) have been observed in retinal an

224 I) using an intraoperative injection of free indocyanine green (ICG) in the detection of peritoneal m

225 sed signal strength by as much as 36.3%, and indocyanine green (ICG) increased signal magnitudes by a

226 ceived 0.5 mg per kilogram of body weight of indocyanine green (ICG) intravenously 24 hours prior to

227 Indocyanine green (ICG) is a fluorescent dye taken up an

228 on and lower autofluorescence; however, only indocyanine green (ICG) is clinically approved.

229 trapping ability of CM, the photosensitizer indocyanine green (ICG) is successfully loaded and retai

230 Indocyanine green (ICG) is the most commonly used FDA-ap

231 Indocyanine green (ICG) is the only near-infrared (NIR)

232 Indocyanine green (ICG) is the only NIR dye with regulat

233 normal female volunteers underwent bilateral indocyanine green (ICG) lymphography and lymphoscintigra

234 ymphatic drainage was measured at day 60 via indocyanine green (ICG) lymphography, after which animal

235 -enhanced Raman scattering (SERS) studies on indocyanine green (ICG) on colloidal silver and gold and

236 The data indicated that (1) formulated indocyanine green (ICG) readily penetrated hyperkeratoti

237 study was to evaluate the performance of the indocyanine green (ICG) retention test as a noninvasive

238 Both indocyanine green (ICG) solution and TA suspension, at 5

239 Indocyanine green (ICG) stain was used in 22 eyes (25.2%

240 (GQDs), directing site-selective assembly of indocyanine green (ICG) that turns on photoinduced elect

241 Indocyanine green (ICG) was administered intravenously 1

242 to evaluations, hamsters were injected with indocyanine green (ICG), a fluorescent dye that binds to

243 as been uniquely accomplished with NIR using indocyanine green (ICG), a nonspecific dye that has comp

244 tiated to RPE (hiPSC-RPE) cells labeled with indocyanine green (ICG), an FDA approved dye, were trans

245 Here we report that indocyanine green (ICG), an infrared fluorescent dye wit

246 nd Drug Administration-approved dyes such as indocyanine green (ICG), but has a caveat of suboptimal

247 lowly releasing a pressurized cuff occluding indocyanine green (ICG), demonstrated an increase in ves

248 tein (GFP), tricarbocyanine 5.5 (Cy5.5), and indocyanine green (ICG), filters were selected to allow

249 yaluronic acid (HA)-dopamine (HD), including indocyanine green (ICG), were developed for local therap

250 e well-known and widely used fluorescent dye indocyanine green (ICG), which has FDA approval, exhibit

251 traprostatic tracer administration of either indocyanine green (ICG)-(99m)Tc-nanocolloid (hybrid-trac

252 ntraprostatic injection of the hybrid tracer indocyanine green (ICG)-(99m)Tc-nanocolloid enables both

253 ng that the hybrid sentinel node (SN) tracer indocyanine green (ICG)-(99m)Tc-nanocolloid generates te

254 al use of SNB, either with the hybrid tracer indocyanine green (ICG)-(99m)Tc-nanocolloid or with free

255 The fluorophore outperformed indocyanine green (ICG)-a clinically approved NIR-I dye-

256 rs, and 24 hours after systemic injection of indocyanine green (ICG).

257 rupted bile excretion of the fluorescent dye indocyanine green (ICG).

258 ear infrared fluorescence (NIR) images using Indocyanine green (ICG).

259 leted mice erythrocyte-ghosts and doped with Indocyanine Green (ICG).

260 ugated with a near-infrared fluorescent dye [indocyanine green (ICG)] targets low extracellular pH, a

261 Fluorescein (FA) and indocyanine green (ICGA) angiography (Heidelberg Spectra

262 direct cannulation, perivascular flowprobe, indocyanine green imaging, and functional magnetic reson

263 systemic injection of the near-infrared dye indocyanine green in patients with various types of soli

264 l subcutaneous injections of 0.31-100 microg indocyanine green in the breast in this IRB-approved, HI

265 As such, simultaneous use of cyanine-5 and indocyanine green in the same patient proved to be feasi

266 h monkey was given a 0.75 mg/kg injection of indocyanine green in the saphenous vein.

267 uation of biodistribution and clearance with indocyanine green indicated that VAB administration may

268 Hepatic blood flow was determined by indocyanine green infusion.

269 l retrospective studies, the fluorescent dye indocyanine green is considered a possible alternative t

270 nt for use in surgery, pHLIP ICG, where ICG (indocyanine green) is a surgical fluorescent dye used wi

271 Using relatively high doses of indocyanine green, long-term enhanced fluorescence of ar

272 he tibial fracture sites using near-infrared indocyanine green lymphatic imaging (NIR-ICG) and discov

273 h dermal backflow of lymph was identified by indocyanine green lymphography, relative to those in the

274 FLT imaging with indocyanine green may improve the accuracy of cancer sur

275 Lymph imaging consistently failed with indocyanine green microdosages between 0.31 and 0.77 mic

276 is context, we propose evaluating the use of Indocyanine Green near-infrared (ICG-NIR) as a supplemen

277 ontrast-enhanced magnetic resonance imaging, indocyanine green near-infrared imaging, and intravital

278 In patients who received 10 microg of indocyanine green or more, a weak negative correlation b

279 By the direct Fick, or the indocyanine-green or both, methods and by renal clearanc

280 gent mixture composed of fluorescein sodium, indocyanine green, PCM102, and PCM107 and imaged with a

281 t the pH low-insertion peptide conjugated to indocyanine green (pHLIP ICG), currently in clinical tri

282 ctant Survanta(R) reduced the aPDT effect of indocyanine green, Photodithazine(R), bacteriochlorin-tr

283 tic function (transpulmonary thermodilution, indocyanine green plasma disappearance rate [ICG-PDR]) w

284 Immediately after administration, indocyanine green provided a significant increase in the

285 /-0.5 vs. 33.2+/-1.7 microg/min/g liver) and indocyanine green secretion (11.7+/-1.7 vs. 21.2+/-2.1 A

286 usion model, lactate dehydrogenase activity, indocyanine green secretion, and portal pressure values

287 of the feature sizes of a common NIR I dye (indocyanine green) showed a more rapid loss of feature c

288 antitative liver function tests, such as the indocyanine green test and galactose elimination capacit

289 Compared to clinically used indocyanine green, the QDs show superior brightness and

290 , and an ex vivo spectrophotometric assay of indocyanine green uptake (1.87-fold increase in normaliz

291 ated similar hyaluronic acid uptake, whereas indocyanine green uptake was markedly impaired in the hy

292 perfusion) and in vivo (hyaluronic acid and indocyanine green uptake, arterial ketone body ratio, or

293 nanocolloid or (99m)Tc-nanocolloid with free indocyanine green used as tracers.

294 assessed clinically, photometrically, and by indocyanine green videoangiography.

295 At anesthesia induction, indocyanine green was injected intravenously.

296 f the widely used label tdTomato and the dye indocyanine green, we show the importance of correct pho

297 yaluronic acid-coated gold nanoparticles and indocyanine green, which is widely used as a dye in vitr

298 nsitive amphiphilic polymer, conjugated with indocyanine green, which rapidly and irreversibly dissoc

299 that contained micromolar concentrations of indocyanine green with 1:0 and 100:1 target-to-backgroun

300 licability of aPDT using the photosensitizer indocyanine green with infrared light has been successfu